Redefining Quality — Implications of Recent Clinical Trials
Authors:
- Thomas H. LeeTLThomas H. Lee
- 12 June 2008
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (24) , 2537-2539
Abstract
Simple approaches to patient care are better — except when they are not. Recent clinical studies are leading to a reexamination of the paradigm whereby efforts to prevent vascular disease focus on the achievement of particular levels of risk factors such as low-density lipoprotein (LDL) cholesterol, systolic blood pressure, and glycated hemoglobin. Although these factors and their levels are important determinants of the development and progression of vascular disease, it is increasingly apparent that the specific strategies used to modify them make a critical difference in patient outcomes. This insight has implications for clinical practice, performance measurement, and regulatory requirements.Keywords
This publication has 7 references indexed in Scilit:
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsNew England Journal of Medicine, 2008
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007
- AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 UpdateCirculation, 2006
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004